A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)

Conditions

Ovary

Phase III

Volunteers
Health Professionals

What is the purpose of this trial?

This is a randomize, double-blind Phase 3 study to compare the efficacy and safety of AVB-S6-500 in combination with paclitaxel (Pac) versus placebo in combination with Pac in patients with platinum resistant recurrent ovarian cancer.

Ages
18 years and older
Gender
Female only

Find out more about who can participate in this trial

Trial with
Aravive, Inc.
Start Date
11/11/2021
End Date
07/24/2023

For more information about this study, contact:

Elizabeth Vitale

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Gary Altwerger, MD
Assistant Professor of Obstetrics and Gynecology; Wellness committee, Obstetrics, Gynecology & Reproductive Sciences

Sub-Investigators

Last Updated
11/12/2021
Study HIC
#2000030390

A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information